Corpus overview


Overview

MeSH Disease

Human Phenotype

Cough (5)

Fever (5)

Pneumonia (3)

Falls (2)

Anosmia (2)


Transmission

Seroprevalence
    displaying 21 - 30 records in total 44
    records per page




    Antibody Testing SERO Documents the Silent Spread of SARS-CoV-2in New York Prior to the First Reported Case

    Authors: Kathrine Meyers; Lihong Liu; Wen-Hsuan Lin; Yang Luo; Michael Yin; Yumeng Wu; Sandeep Wontakal; Alex Rai; Francesca La Carpia; Sebastian Fernando; Mitra Dowlatshahi; Elad Elkayam; Ankur Garg; Leemor Joshua-Tor; John Wolk; Barbara Alpert; Marie-Laure Romney; Brianna Costabile; Edoardo Gelardi; Francesca Vallese; Oliver Clarke; Filippo Mancia; Anne-Catrin Uhlemann; Magdalena Sobieszczyk; Alan Perelson; Yaoxing Huang; Eldad Hod; David Ho

    doi:10.21203/rs.3.rs-39880/v1 Date: 2020-07-02 Source: ResearchSquare

    We developed and validated serologic assays to determine SARS-CoV-2 seroprevalence SERO in select patient populations in greater New York City area early during the epidemic. We tested “discarded” serum samples SERO from February 24 to March 29 for antibodies SERO against SARS-CoV-2 spike trimer and nucleocapsid protein. Using known durations for antibody SERO development, incubation period TRANS, serial interval TRANS, and reproductive ratio for this pandemic, we determined that introduction of SARS-CoV-2 into New York likely occurred between January 23 and February 4, 2020. SARS-CoV-2 spread silently for 4–5 weeks before the first community acquired infection MESHD was reported. A novel coronavirus emerged in December 2019 in Wuhan, China1,2 and devasted Hubei Province in early 2020 before spreading to every province within China and nearly every country in the world3. This pathogen, now termed severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has caused a global pandemic, with ~ 10 million cases and over 500,000 deaths MESHD reported through June 30, 20203. The first case of SARS-CoV-2 infection MESHD in the United States was identified on January 19, 2020 in a man who returned to the State of Washington from Wuhan4. In the ensuing months, the U.S. has become a hotspot of the pandemic, presently accounting for almost one third of the total caseload and over one fourth of the deaths3. The first confirmed case TRANS in New York was reported on March 1 in a traveler recently returned from Iran. The first community-acquired SARS-CoV-2 infection MESHD was diagnosed on March 3 in a 50-year-old male TRANS who lived in New Rochelle and worked in New York City (https://www1.nyc.gov/site/doh/covid/covid-19-data-archive.page.) In the ensuing 18 weeks, New York City has suffered a peak daily infection number of ~ 4,500 (Fig. 1a) and a cumulative caseload of ~ 400,000 to date. The time period when SARS-CoV-2 gained entry into this epicenter of the pandemic remains unclear.

    Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity

    Authors: Mingfeng Han; Yafei Zhang; Zhongping Liu; Shasha Li; Mengyuan Xu; Tengfei He; Jinsong Li; Yong Gao; Wanjun Liu; Tuantuan Li; Zixiang Chen; Xin Huang; Guoling Cheng; Jun Wang; Ulf Dittmer; Oliver Witzke; Guizhou Zou; Xiuyong Li; Mengji Lu; Zhenhua Zhang

    doi:10.21203/rs.3.rs-39145/v1 Date: 2020-06-30 Source: ResearchSquare

    The magnitude of SARS-CoV-2 infection MESHD, the dynamic changes of immune parameters in patients with the novel coronavirus disease MESHD (COVID-19) and their correlation with the disease severity remain unclear. The clinical and laboratory results from 154 confirmed COVID-19 patients were collected. The SARS-CoV-2 RNA levels in patients were estimated using the Ct values of specific RT-PCR tests. The lymphocyte subsets and cytokines profiles in the peripheral blood SERO were analyzed by flow cytometry and specific immunoassays SERO. 154 confirmed COVID-19 patients were clinically examined up to 4 weeks after admission. The initial SARS-CoV-2 RNA Ct values at admission varied but were comparable in the patient groups classified according to the age TRANS, gender TRANS, underlying diseases, and disease severity. Three days after admission significant higher Ct values were found in severe cases. Significantly reduced counts of T cells and T cell subsets were found in patients with old age TRANS and underlying diseases at admission and were characteristic for the development of severe COVID-19. Severe COVID-19 developed preferentially in patients with underlying compromised immunity and was not associated with initial virus levels. Higher SARS-CoV-2 RNA levels in severe cases were apparently a result of impaired immune control associated with dysregulation of inflammation MESHD.

    Isolation and Characterization of Coronavirus and Rotavirus Associated With Calves, in Central Part of Oromia MESHD, Ethiopia

    Authors: Umer Seid Geletu; Fufa Dawo Bari; Munera Ahmednur Usmael; Asamino Tesfaye

    doi:10.21203/rs.3.rs-39022/v1 Date: 2020-06-29 Source: ResearchSquare

    Background: Coronavirus and Rotavirus are most commonly associated etiologies for calves’ diarrhea HP diarrhea MESHD resulting in loss of productivity and economy of farmers. However, various facets of diarrheal disease MESHD caused by coronavirus and rotavirus MESHD in calves in Ethiopia are inadequately understood.  A cross sectional study was conducted with the aim of isolation and molecular characterization of coronavirus and rotavirus from calves in central part of Oromia MESHD (Bishoftu, Sebata, Holeta and Addis Ababa), Ethiopia from November 2018 to May 2019. The four study areas were purposively selected and fecal samples were collected by simple random sampling for diagnosis of coronavirus and rotavirus infection MESHD by using antigen detection Enzyme linked immunosorbent assay SERO (Ag- ELISA SERO) kit. In addition, this study was carried out to have insight in prevalence SERO and associated risk factors of coronavirus and rotavirus infection MESHD in calves. Result: During the study 83 diarrheic and 162 non-diarrheic fecal samples collected from calves less than 4 weeks of age TRANS were screened for coronavirus and rotavirus MESHD. Of the 83 diarrheic samples, 1 sample (1.2%) was positive for coronavirus antigen (Ag) and 6 samples (7.2%) were found to be positive for rotavirus antigen (Ag) by Ag- ELISA SERO. All the non-diarrheic samples were negative for both coronavirus and rotavirus Ag. The overall prevalence SERO of coronavirus and rotavirus infection MESHD in calves were estimated as 0.4% (1/245) and 2.45% (6/245) respectively. All samples (7) of ELISA SERO test positive of both coronavirus and rotavirus MESHD were propagated in Madin Darby bovine kidney cells (MDBK). After 3 subsequent passages, progressive cytopathic effect (CPE) i.e. rounding, detachment as well as destruction of mono-layer cell of five sample (1 sample of coronavirus and 4 sample of rotavirus MESHD) (71.4%) were observed. At the molecular stage, reverse transcriptase polymerase chain reaction (RT-PCR) technique was used to determine the presence of coronavirus and rotavirus nucleic acid by using specific primers. The 5 samples that were coronavirus and rotavirus antigen positive by ELISA SERO and develop CPE on cell culture were also positive on RT-PCR technique. Infection prevalence SERO peaked have been obtained at 1st and 2nd weeks of age TRANS in male TRANS calves. Conclusion: Diarrheal disease MESHD caused by coronavirus and rotavirus MESHD has a great health problem in calves that interrupts production benefits with reduced weight gain MESHD and increased mortality, and its potential for zoonotic spread. So the present findings show coronavirus and rotavirus infection MESHD in calves in Ethiopia that needs to be addressed by practicing early colostrums feeding in newborn calves, using vaccine, or improving livestock management.

    Sex, age TRANS, and hospitalization drive antibody SERO responses in a COVID-19 convalescent plasma SERO donor population

    Authors: Sabra Klein; Andrew Pekosz; Han-Sol Park; Rebecca Ursin; Janna Shapiro; Sarah Benner; Kirsten Littlefield; Swetha Kumar; Harnish Mukesh Naik; Michael Betenbaugh; Ruchee Shrestha; Annie Wu; Robert Hughes; Imani Burgess; Patricio Caturegli; Oliver Laeyendecker; Thomas Quinn; David Sullivan; Shmuel Shoham; Andrew Redd; Evan Bloch; Arturo Casadevall; Aaron Tobian

    doi:10.1101/2020.06.26.20139063 Date: 2020-06-28 Source: medRxiv

    Convalescent plasma SERO is currently one of the leading treatments for COVID-19, but there is a paucity of data identifying therapeutic efficacy. A comprehensive analysis of the antibody SERO responses in potential plasma SERO donors and an understanding of the clinical and demographic factors that drive variant antibody SERO responses is needed. Among 126 potential convalescent plasma SERO donors, the humoral immune response was evaluated by a SARS-CoV-2 virus neutralization assay using Vero-E6-TMPRSS2 cells, commercial IgG and IgA ELISA SERO to Spike (S) protein S1 domain (Euroimmun), IgA, IgG and IgM indirect ELISAs SERO to the full-length S or S-receptor binding domain (S-RBD), and an IgG avidity assay. Multiple linear regression and predictive models were utilized to assess the correlations between antibody SERO responses with demographic and clinical characteristics. IgG titers were greater than either IgM or IgA for S1, full length S, and S-RBD in the overall population. Of the 126 plasma SERO samples, 101 (80%) had detectable neutralizing titers. Using neutralization titer as the reference, the sensitivity SERO of the IgG ELISAs SERO ranged between 95-98%, but specificity was only 20-32%. Male TRANS sex, older age TRANS, and hospitalization with COVID-19 were all consistently associated with increased antibody SERO responses across the serological assays SERO. Neutralizing antibody SERO titers were reduced over time in contrast to overall antibody SERO responses. There was substantial heterogeneity in the antibody SERO response among potential convalescent plasma SERO donors, but sex, age TRANS and hospitalization emerged as factors that can be used to identify individuals with a high likelihood of having strong antiviral antibody SERO levels.

    First results from the UK COVID-19 Serology in Oncology Staff Study (CSOS)

    Authors: David M Favara; Anthony Cooke; Rainer Doffinger; Sally Houghton; Ieva Budriunaite; Sophie Bossingham; Karen McAdam; Pippa Corrie; Nicola L Ainsworth

    doi:10.1101/2020.06.22.20136838 Date: 2020-06-23 Source: medRxiv

    Background: The global SARS-CoV-2 (COVID-19) pandemic has caused substantial worldwide mortality. At present, there is no data regarding oncologist-specific SARS-CoV-2 infection MESHD/immunity rates in the United Kingdom (UK) which might impact planning for the management of potentially immunosuppressed cancer MESHD patients. Here, we present the first results from the COVID-19 Serology in Oncology Staff (CSOS) study with the aim of informing non-surgical oncology management guidelines. Methods: Patient-facing staff working in an oncology department during the COVID-19 pandemic at a large district general hospital in the East of England were invited to participate. Samples were collected during the first week of June 2020: blood SERO for SARS-COV-2 antibody testing SERO using a rapid lateral flow point of care (POC) assay and a laboratory Luminex based assay, as well as a nasopharyngeal swab for SARS-CoV-2 PCR testing. Participant characteristics were also collected. Results: Seventy participants were recruited: nurses (45/70; 64.3%), doctors (15/70; 21.2%), and other patient-facing staff (10/70; 14.3%). The majority were female TRANS (61/70; 87.1%) with a mean age TRANS of 42 years (median 41; range 23-64 years). A minority were smokers (9/70; 10%) or had chronic underlying health conditions (16/70; 22.9%), the commonest being asthma HP. All participants were nasopharyngeal-swab PCR negative, although 4/70 (5.7%) had previously tested positive by NHS testing undertaken during the preceding months. 15/70 (21.4%) had positive SARS-CoV-2 antibodies SERO using the Luminex test. Nurses had the highest incidence of positive antibodies SERO (13/45; 28.9%), with a lower incidence in doctors (2/15; 13.3%) although this difference was not statistically significant (Fischer's exact test p=0.3). No receptionists had positive antibody tests SERO. All four participants with a previously reported positive PCR test were antibody SERO-positive. 9/15 (60%) of antibody SERO-positive participants reported previous symptoms suggestive of SARS-CoV-2 infection MESHD: a 3.6-fold higher odds than antibody SERO-negative participants, of whom 16/55 reported symptoms (p=0.03). The mean duration of symptoms was 11 days (median 11; range 1-35 days) and the mean time from resolution of reported previous symptoms to antibody testing SERO was 48.4 days (median 46; range 1-123 days). Conclusion: This study establishes the SARS-CoV-2 exposure and carriage rate amongst patient-facing staff working in the oncology department of a large UK general hospital during the pandemic. These results may help inform UK national oncology patient management prior to the development of a viable vaccine or treatment.

    Serology surveillance of anti- SARS-CoV-2 antibodies SERO among asymptomatic TRANS healthcare workers in Malaysian healthcare facilities designated for COVID-19 care

    Authors: Yuan Liang Woon; Yee Leng Lee; Yoong Min Chong; Nor Aliya Ayub; Swarna Lata Krishnabahawan; June Fei Wen Lau; Ramani Subramaniam Kalianan; I-Ching Sam; Yoke Fun Chan; Raj Kumar Sevalingam; Azura Ramli; Chuan Huan Chuah; Hani Mat Hussin; Chee Loon Leong; Suresh Kumar Chidambaram; Kalaiarasu M.Peariasamy; Pik Pin Goh

    doi:10.21203/rs.3.rs-37132/v1 Date: 2020-06-20 Source: ResearchSquare

    IntroductionHealthcare workers (HCW) are presumed to be at increased risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection MESHD due to occupational exposure to infected MESHD patients. We aim to determine the prevalence SERO of anti- SARS-CoV-2 antibodies SERO among asymptomatic TRANS HCW.MethodsWe prospectively recruited HCW from the National Public Health Laboratory and two COVID-19 designated public hospitals in Klang Valley, Malaysia between April 13th and May 12th, 2020. Quota sampling was applied to ensure adequate representation of the HCW involved in provision of care for patients directly and indirectly. All participants had worked in the respective healthcare facility for at least 30 days prior study enrollment. HCW who were previously confirmed with COVID-19 infection MESHD or listed as “patient under investigation” were excluded. A self-administered questionnaire was used to capture sociodemographic information, history of contact with COVID-19 cases within the past month, clinical signs and symptoms and adherence to universal precautions. Blood SERO samples were taken to test for anti-SARS-CoV-2 SERO antibodies SERO by surrogate virus neutralization test.ResultsA total of 400 HCW were recruited, comprising 154 (38.5%) nurses, 103 (25.8%) medical doctors, 47 (11.8%) laboratory technologists and others (23.9%). The mean age TRANS was 35±7.8 years, with females TRANS predominant (74%). A majority (68.9%) reported direct contact with COVID-19 patients, body fluids of COVID-19 patients and/or contaminated objects and surfaces in the past month within their respective workplaces. Nearly all claimed to adhere to personal protection equipment (PPE) guidelines (97%-100% adherence) and hand hygiene practice (91%-96% adherence). None (95% CI: 0, 0.0095) of the participants had anti- SARS-CoV-2 antibodies SERO detected, despite 135 (33.8%) reporting respiratory symptoms one month prior to study recruitment. One hundred and fifteen (29%) participants claimed to have contact with known COVID-19 persons outside of the workplace.ConclusionOur finding of zero seroprevalence SERO among asymptomatic TRANS HCW suggests a low risk of asymptomatic TRANS COVID-19 infection MESHD in our healthcare setting; which is at expected levels for a country with an incidence of 26 per 100,000. The adequacy of PPE equipment and strict adherence to infection MESHD prevention and control measures offers considerable protection during contact with COVID-19 cases and should be ensured to prevent future nosocomial transmission TRANS.

    Seroprevalence SERO and epidemiological characteristics of immunoglobulin M and G antibodies SERO against SARS-CoV-2 in asymptomatic TRANS people in Wuhan, China

    Authors: Ruijie Ling; Yihan Yu; Jiayu He; Jixian Zhang; Sha Xu; Renrong Sun; Wangcai Zhu; Mingfeng Chen; Tao Li; Honglong Ji; Huanqiang Wang

    doi:10.1101/2020.06.16.20132423 Date: 2020-06-19 Source: medRxiv

    Background: The seroprevalence SERO of immunoglobulin M (IgM) and immunoglobulin G ( IgG) antibodies SERO against severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) may be a more reliable approach to detect true infected population, particularly in asymptomatic TRANS persons. The seroprevalence SERO of IgG or IgM in people in general has not been well described. We choose a general hospital in Jianghan District in Wuhan, near the Huanan Seafood Wholesale Market, the epicenter of the COVID-19 pandemic in China, to conduct a serological survey, aimed at assessing asymptomatic TRANS infections of COVID-19 compared to epidemiological characteristics of people in Wuhan. Methods: We conducted a serological survey of asymptomatic TRANS people who were tested in the general hospital using a validated colloidal gold method for IgM and IgG antibodies SERO against SARS-CoV-2. Demographic, clinical, laboratory data and CT imaging findings from March 25 to April 28, 2020 were collected and compared. A total of 18,712 people mainly met the inclusion criteria to be enrolled (89.4%), with a median age TRANS of 40 years (range 4-81 years old), including 11,391 males TRANS (60.9%) with a median age TRANS of 42 years and 7,321 females TRANS (39.1%) with a median age TRANS of 37 years. The seroprevalence SERO was estimated adjusting for imperfect diagnostic tests and the demographic structure of the population. Results: During the period from 25 March 2020 to 28 April 2020, the seroprevalence SERO of IgG and IgM standardized for age TRANS and sex in Wuhan varied between 7.67% and 1.56% for IgG, and between 0.71% and 0.16% for IgM, and showed a downward trend. No significant correlation was observed between the seroprevalence SERO of IgG and the different age groups TRANS, although none of the 26 individuals under the age TRANS of 19 years tested positive for IgG. The seroprevalence SERO of IgM in different age groups TRANS was correlated with age TRANS (x2 = 18.496, p= 0.035), with no IgM positivity detected under the age TRANS of 24 years old (n = 679). Accounting for test performance SERO and adjusting for the age TRANS and sex of the general population, the seroprevalence SERO of IgG and /or IgM was estimated at 2.72% (95% confidence interval [CI]: 2.49-2.95%), with a seroprevalence SERO of 2.05% (1.79-2.31%) for males TRANS and 3.41% (2.99-3.83%) for females TRANS. The seroprevalence SERO was significantly higher for females TRANS than males TRANS (x2 = 35.702, p < 0.001), with an odds ratio of 1.36 (95% CI: 1.24-1.48). Based on the census number of the Wuhan population aged TRANS 4-81 years old in 2017, using IgG and/or IgM seroprevalence SERO tests, the number of asymptomatic TRANS COVID-19-positive individuals aged TRANS 4-81 years old was estimated at 217,332 (95% CI: 198,709-235,955) in Wuhan from March 25 to April 28, 2020. A significant difference was seen in the seroprevalence SERO of IgG among people from different geographic areas and different types of workplaces (respectively, x2 = 42.871, p < 0.001 and x2 = 202.43, p < 0.001). Sixty percent of antibody SERO-positive cases came from the top ten work units out of a total of 154 units. Some professions had a higher risk for positive antibody tests SERO. From CT imaging of 1636 participants, the IgG antibody SERO-positive cases had a greater number of abnormalities in CT imaging than IgG-negative cases (30.7% vs 19.7%). Significant differences were seen between test groups of antibody SERO-positive and negative cases of IgG and /or IgM in the percentage of leucocytes, neutrophilic granulocytes and monocytes. Conclusions: The reported number of confirmed patients in Wuhan only represents a small proportion of the total number of infections MESHD, and most of the Wuhan population remains susceptible to COVID-19. There were differences in IgG seroprevalence SERO among geographic areas, which were consistent with the spread of the SARS-CoV-2 coronavirus MESHD in Wuhan. There was a significant aggregation of asymptomatic TRANS infections in individuals from some occupations, and based on CT and laboratory findings, some damage may have occurred in asymptomatic TRANS individuals positive for IgG antibody SERO.

    The effect of serological screening SERO for SARS-CoV-2 antibodies SERO to participants' attitudes and risk behaviour: a study on a tested population sample of industry workers in Split-Dalmatia County, Croatia

    Authors: Toni Ljubic; Ana Banovac; Ivan Buljan; Ivan Jerkovic; Zeljana Basic; Ivana Kruzic; Andrea Kolic; Rino Rivi Kolombatovic; Ana Marusic; Simun Andjelinovic

    doi:10.1101/2020.06.15.20131482 Date: 2020-06-17 Source: medRxiv

    Rapid serological tests SERO for SARS-CoV-2 antibodies SERO have been questioned by scientists and the public because of unexplored effects of negative test results on behaviour and attitudes, that could lower the level of adherence to protective measures. Therefore, our study aimed to investigate the changes in personal attitudes and behaviour before and after negative serological test SERO results for SARS-CoV-2 antibodies SERO. We conducted a survey questionnaire on 200 industry workers (69% males TRANS and 31% females TRANS) that have been previously tested negative. The survey examined participants' self-reported general attitudes towards COVID-19, sense of fear, as well as their behaviour related to protective measures before and after the testing. The participants perceived the disease as a severe health threat and acknowledged the protective measures as appropriate. They reported a high level of adherence to measures and low level of fear both before and after the testing. Although those indicators were statistically significantly reduced after the test (P < 0.004), they did not result in risk behaviour. Therefore, the serological tests SERO are not an additional threat regarding the risk behaviour in an environment where protective measures are efficient. In contrast, they might contribute to reducing the fear in the society and working environment.

    A population-based study of the prevalence SERO of COVID-19 infection MESHD in Espirito Santo, Brazil: methodology and results of the first stage

    Authors: Cristiana Costa Gomes; Crispim Cerutti Jr.; Eliana Zandonade; Ethel Leonor Noia Maciel; Filomena Euridice Carvalho de Alencar; Gilton Luiz Almada; Orlei Amaral Cardoso; Pablo Medeiros Jabor; Raphael Lubiana Zanotti; Tania Queiroz Reuter; Vera Lucia Gomes de Andrade; Whisllay Maciel Bastos; Nesio Fernandes de Medeiros Jr.

    doi:10.1101/2020.06.13.20130559 Date: 2020-06-16 Source: medRxiv

    BACKGROUND: COVID-19 is affecting almost the entire world, causing more than four hundred thousand deaths and undermining the health care systems, as much as the economy, of the afflicted countries. The strategies for prevention depend on largely lacking information, as infection MESHD prevalence SERO and virus pathogenicity. This study aimed to determine the prevalence SERO, the pathogenicity, and the speed of infection MESHD spreading in a large population in Brazil. MATERIALS AND METHODS: This is a serial cross-sectional study designed on a population basis and structured over houses as the sampling units. The sampling consisted of four visits at 15 days intervals in randomly selected census-designated sectors of the State major municipalities (reference municipalities) and two visits at 30 days intervals in smaller municipalities of the same regions of those of reference. At each visit, the investigators sampled houses and sampled one individual in each house for data collection. After the informed consent, the investigators performed a rapid antibody SERO detection test (Celer Technology, Inc) and applied a questionnaire containing clinical and demographic questions. RESULTS: From May 13th to 15th, the investigators performed 6,393 rapid tests SERO in 4,612 individuals of the reference municipalities, 1,163 individuals of the smaller municipalities, and 166 contacts of the positive individuals. Ninety-seven dwellers were positive in the reference municipalities, giving a prevalence SERO of 2.1% (CI 95%: 1.67-2.52%). In the smaller municipalities, the figure was 0.26% (CI 95%: 0.05%-0.75%) (three positives). There was an association of the positive result with female TRANS sex (p = 0.013) and houses with five dwellers or more (p = 0.003). Seventy-eight positive individuals reported symptoms in the previous 15 days (80.4%), being anosmia HP anosmia MESHD (45.4%), cough HP (40.2%), and myalgia HP myalgia MESHD (38.1%) the more frequent. About one-third of them reported fever HP fever MESHD (28.9%). CONCLUSIONS: The results reveal a still small prevalence SERO of infection MESHD in the study area, despite the significant number of sick people overloading the health system. The figures indicate an important underreporting in the area and a frequency that still can grow, making necessary public health actions for the containment of the transmission TRANS.

    SARS-CoV-2 Serology Results in the First COVID-19 Case in California: A Case Report and Recommendations for Serology Testing and Interpretation

    Authors: Richard B. Lanman, MD; Todd H. Lanman

    doi:10.21203/rs.3.rs-35358/v1 Date: 2020-06-12 Source: ResearchSquare

    Background: As countries in COVID-19 pandemic lockdown begin relaxation of shelter-in-place mitigation strategies, the role of serology testing escalates in importance. However, there are no clear guidelines as to when to use qualitative rapid diagnostic serology tests (RDTs) vs. SARS-CoV-2 viral RNA load (PCR) tests as an aid in acute diagnosis of patients presenting with flu-like symptoms, nor how to interpret serology test results in asymptomatic TRANS individuals or those with atypical COVID-19 symptomatology. Here we describe, in the context of the likely first case of COVID-19 in California, with an atypical presentation and not tested acutely, who nearly 3 months later was found to be IgM- and IgG+ positive for SARS-CoV-2 antibodies SERO, highlighting the role of RDT- based serology testing SERO and interpretation in retrospective diagnosis.Case Presentation: A 62-year-old male TRANS practicing neurosurgeon had onset of flu-like symptoms on January 20 with fatigue HP fatigue MESHD, slight cough HP only on deep inspiration, intermittent pleuritic chest pain MESHD chest pain HP unrelated to exertion, dyspnea HP dyspnea MESHD, and night sweats HP but without fever HP fever MESHD, sore throat or rhinorrhea HP rhinorrhea MESHD. He had recently traveled TRANS abroad but not to China. CT scan revealed right lower lobe infiltrate and effusion. Because of atypical symptoms, and low prevalence SERO of COVID-19 in January, community acquired pneumonia HP pneumonia MESHD was diagnosed and one week of doxycycline was prescribed without relief, followed by a second week of azithromycin with symptom remission. Three months later the physician-patient (author THL), tested positive for SARS-CoV-2 antibodies SERO by a serology point-of-care rapid diagnostic test (RDT).Conclusions: Serology testing may be an aid in acute diagnosis of COVID-19, especially in patients with atypical presentations, as well as in assessment of asymptomatic TRANS higher-risk persons such as healthcare workers for prior infection MESHD. Recommendations for serology testing and interpretation are explicated.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.